Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 5
2019 17
2020 24
2021 29
2022 11
2023 20
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed.
Borghetti A, Ciccullo A, Lombardi F, Giannarelli D, Passerotto RA, Lamanna F, Carcagnì A, Farinacci D, Dusina A, Baldin G, Zazzi M, Di Giambenedetto S. Borghetti A, et al. Among authors: ciccullo a. Open Forum Infect Dis. 2024 Apr 10;11(5):ofae198. doi: 10.1093/ofid/ofae198. eCollection 2024 May. Open Forum Infect Dis. 2024. PMID: 38680613 Free PMC article.
Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistant Acinetobacter baumannii in HIV and COVID 19 infected patient: A case report.
Passerotto RA, Lamanna F, Farinacci D, Dusina A, Di Giambenedetto S, Ciccullo A, Borghetti A. Passerotto RA, et al. Among authors: ciccullo a. Infect Med (Beijing). 2023 Jun;2(2):143-147. doi: 10.1016/j.imj.2023.02.004. Epub 2023 Mar 4. Infect Med (Beijing). 2023. PMID: 38013739 Free PMC article.
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
Ciccullo A, Baldin G, Borghi V, Oreni L, Lagi F, Fusco P, Giacomelli A, Torti C, Sterrantino G, Mussini C, Antinori S, Di Giambenedetto S. Ciccullo A, et al. Int J Antimicrob Agents. 2024 Jan;63(1):107040. doi: 10.1016/j.ijantimicag.2023.107040. Epub 2023 Nov 20. Int J Antimicrob Agents. 2024. PMID: 37981074
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Lagi F, Giacomelli A, Borghi V, Ciccullo A, Taramasso L, Madeddu G, D'Ettorre G, Giacometti A, Ducci F, De Vito A, Pincino R, Di Giambenedetto S, Mussini C, Antinori S, Sterrantino G. Lagi F, et al. Among authors: ciccullo a. J Med Virol. 2023 Oct;95(10):e29149. doi: 10.1002/jmv.29149. J Med Virol. 2023. PMID: 37805832
Malnutrition in COVID-19 survivors: prevalence and risk factors.
Tosato M, Calvani R, Ciciarello F, Galluzzo V, Martone AM, Zazzara MB, Pais C, Savera G, Robles MC, Ramirez M, Landi F; Gemelli Against COVID-19 Post-Acute Care Team. Tosato M, et al. Aging Clin Exp Res. 2023 Oct;35(10):2257-2265. doi: 10.1007/s40520-023-02526-4. Epub 2023 Sep 4. Aging Clin Exp Res. 2023. PMID: 37665556 Free PMC article.
99 results